China Traditional Chinese Medicine Holdings Co. Limited provided consolidated earnings guidance for the six months ended June 30, 2023. Based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 (the "Period"), it is expected that the net profit of the Group for the Period would increase by 45%-55% as compared to that for the same period in 2022.

The Board considers that benefited from the stable domestic macro economy with good momentum for growth, the Group has promoted the gradual recovery of the main business with multiple measures, in which the revenue from the sales of concentrated TCM granules, TCM decoction pieces and TCM finished drugs have obviously increased, and the net profit has increased greatly in the Period.